186 related articles for article (PubMed ID: 10543762)
21. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.
Jones RN; Ballow CH; Biedenbach DJ; Deinhart JA; Schentag JJ
Diagn Microbiol Infect Dis; 1998 Jul; 31(3):437-51. PubMed ID: 9635235
[TBL] [Abstract][Full Text] [Related]
22. Quinupristin-dalfopristin versus linezolid for the treatment of vancomycin-resistant Enterococcus faecium bacteraemia: efficacy and development of resistance.
Chong YP; Lee SO; Song EH; Lee EJ; Jang EY; Kim SH; Choi SH; Kim MN; Jeong JY; Woo JH; Kim YS
Scand J Infect Dis; 2010 Jul; 42(6-7):491-9. PubMed ID: 20524781
[TBL] [Abstract][Full Text] [Related]
23. Comparative in-vitro activity of quinupristin/dalfopristin against Enterococcus spp.
Williams JD; Maskell JP; Whiley AC; Sefton AM
J Antimicrob Chemother; 1997 May; 39 Suppl A():41-6. PubMed ID: 9511061
[TBL] [Abstract][Full Text] [Related]
24. Antimicrobial activity of mupirocin, daptomycin, linezolid, quinupristin/dalfopristin and tigecycline against vancomycin-resistant enterococci (VRE) from clinical isolates in Korea (1998 and 2005).
Lee DK; Kim Y; Park KS; Yang JW; Kim K; Ha NJ
J Biochem Mol Biol; 2007 Nov; 40(6):881-7. PubMed ID: 18047782
[TBL] [Abstract][Full Text] [Related]
25. Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections.
Raad I; Hachem R; Hanna H; Afif C; Escalante C; Kantarjian H; Rolston K
J Antimicrob Chemother; 2004 Apr; 53(4):646-9. PubMed ID: 14998986
[TBL] [Abstract][Full Text] [Related]
26. Intracellular activities of RP 59500 (quinupristin-dalfopristin) and sparfloxacin against Enterococcus faecium.
Herrera-Insúa I; Jacques-Palaz K; Murray BE; Rakita RM
Antimicrob Agents Chemother; 1996 Apr; 40(4):886-90. PubMed ID: 8849245
[TBL] [Abstract][Full Text] [Related]
27. Characterization of vancomycin-resistant Enterococcus faecium isolates from the United States and their susceptibility in vitro to dalfopristin-quinupristin.
Eliopoulos GM; Wennersten CB; Gold HS; Schülin T; Souli M; Farris MG; Cerwinka S; Nadler HL; Dowzicky M; Talbot GH; Moellering RC
Antimicrob Agents Chemother; 1998 May; 42(5):1088-92. PubMed ID: 9593132
[TBL] [Abstract][Full Text] [Related]
28. Comparative in vitro activity of vancomycin and other antimicrobial agents against methicillin-resistant staphylococcus aureus and enterococcus faecium in the Tohoku district of Japan.
Lutfor AB; Kikuchi T; Tokue Y; Takahashi H; Shoji S; Fujimura S; Nukiwa T; Watanabe A
Chemotherapy; 1998; 44(5):318-23. PubMed ID: 9732146
[TBL] [Abstract][Full Text] [Related]
29. Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.
Lamb HM; Figgitt DP; Faulds D
Drugs; 1999 Dec; 58(6):1061-97. PubMed ID: 10651391
[TBL] [Abstract][Full Text] [Related]
30. Influence of erythromycin resistance, inoculum growth phase, and incubation time on assessment of the bactericidal activity of RP 59500 (quinupristin-dalfopristin) against vancomycin-resistant Enterococcus faecium.
Caron F; Gold HS; Wennersten CB; Farris MG; Moellering RC; Eliopoulos GM
Antimicrob Agents Chemother; 1997 Dec; 41(12):2749-53. PubMed ID: 9420051
[TBL] [Abstract][Full Text] [Related]
31. Intra-hospital dissemination of quinupristin/dalfopristin- and vancomycin-resistant Enterococcus faecium in a paediatric ward of a German hospital.
Werner G; Klare I; Spencker FB; Witte W
J Antimicrob Chemother; 2003 Jul; 52(1):113-5. PubMed ID: 12805253
[TBL] [Abstract][Full Text] [Related]
32. Clinical-use-associated decrease in susceptibility of vancomycin-resistant Enterococcus faecium to linezolid: a comparison with quinupristin-dalfopristin.
Raad II; Hanna HA; Hachem RY; Dvorak T; Arbuckle RB; Chaiban G; Rice LB
Antimicrob Agents Chemother; 2004 Sep; 48(9):3583-5. PubMed ID: 15328133
[TBL] [Abstract][Full Text] [Related]
33. Quinupristin/dalfopristin (RP 59500) therapy for vancomycin-resistant Enterococcus faecium aortic graft infection: case report.
Sahgal VS; Urban C; Mariano N; Weinbaum F; Turner J; Rahal JJ
Microb Drug Resist; 1995; 1(3):245-7. PubMed ID: 9158782
[TBL] [Abstract][Full Text] [Related]
34. Experience with quinupristin/dalfopristin in treating infections with vancomycin-resistant Enterococcus faecium in children.
Gray JW; Darbyshire PJ; Beath SV; Kelly D; Mann JR
Pediatr Infect Dis J; 2000 Mar; 19(3):234-8. PubMed ID: 10749466
[TBL] [Abstract][Full Text] [Related]
35. Treatment of endocarditis due to vancomycin-resistant Enterococcus faecium with quinupristin/dalfopristin, doxycycline, and rifampin: a synergistic drug combination.
Matsumura S; Simor AE
Clin Infect Dis; 1998 Dec; 27(6):1554-6. PubMed ID: 9868693
[No Abstract] [Full Text] [Related]
36. Activity of the quinupristin-dalfopristin combination (RP-59500; Synercid) tested against vancomycin-resistant Enterococcus species.
Cormican MG; Johnson DM; Jones RN
Diagn Microbiol Infect Dis; 1996 Jan; 24(1):59-60. PubMed ID: 8988766
[No Abstract] [Full Text] [Related]
37. Vancomycin-resistant Enterococcus faecium osteomyelitis: successful treatment with quinupristin-dalfopristin.
Summers M; Misenhimer GR; Antony SJ
South Med J; 2001 Mar; 94(3):353-5. PubMed ID: 11284529
[TBL] [Abstract][Full Text] [Related]
38. Quinupristin/dalfopristin: therapeutic potential for vancomycin-resistant enterococcal infections.
Moellering RC
J Antimicrob Chemother; 1999 Sep; 44 Suppl A():25-30. PubMed ID: 10511394
[TBL] [Abstract][Full Text] [Related]
39. In vitro activity of quinupristin/dalfopristin and other antibiotics against ampicillin-resistant enterococcus faecium.
Wang FD; Liu IM; Liu CY
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Feb; 63(2):119-23. PubMed ID: 10677922
[TBL] [Abstract][Full Text] [Related]
40. Phenotypic and genotypic characterization of vancomycin-resistant Enterococcus faecium clinical isolates from two hospitals in Mexico: First detection of VanB phenotype-vanA genotype.
Bocanegra-Ibarias P; Flores-Treviño S; Camacho-Ortiz A; Morfin-Otero R; Villarreal-Treviño L; Llaca-Díaz J; Martínez-Landeros EA; Rodríguez-Noriega E; Calzada-Güereca A; Maldonado-Garza HJ; Garza-González E
Enferm Infecc Microbiol Clin; 2016; 34(7):415-21. PubMed ID: 26589756
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
